| Literature DB >> 30624650 |
Abigail J Heithoff1, Steven A Totusek1, Duc Le2, Lucas Barwick3, Gary Gensler3, Donald R Franklin4, Allison C Dye1, Sanjit Pandey2, Seth Sherman3, Chittibabu Guda2,5, Howard S Fox1.
Abstract
Herein we present major updates to the National NeuroAIDS Tissue Consortium (NNTC) database. The NNTC's ongoing multisite clinical research study was established to facilitate access to ante-mortem and post-mortem data, tissues and biofluids for the neurohuman immunodeficiency virus (HIV) research community. Recently, the NNTC has expanded to include data from the central nervous system HIV Antiretroviral Therapy Effects Research (CHARTER) study. The data and biospecimens from CHARTER and NNTC cohorts are available to qualified researchers upon request. Data generated by requestors using NNTC biospecimens and tissues are returned to the NNTC upon the conclusion of requestors' work, and this external, experimental data are annotated and curated in the publically accessible NNTC database, thereby extending the utility of each case. A flexible and extensible database ontology allows the integration of disparate data sets, including external experimental data, clinical neuropsychological and neuromedical testing data, tissue pathology and neuroimaging data.Entities:
Mesh:
Year: 2019 PMID: 30624650 PMCID: PMC6323298 DOI: 10.1093/database/bay134
Source DB: PubMed Journal: Database (Oxford) ISSN: 1758-0463 Impact factor: 4.462
Selected demographic and HIV disease characteristics of the CHARTER and NNTC clinical research populations.
| CHARTER cross-sectional cohort | Active NNTC cohort | Longitudinal NNTC cohort | NNTC tissue bank cohort | |||||
|---|---|---|---|---|---|---|---|---|
| Demographics and HIV characteristics: |
| Percentage |
| Percentage |
| Percentage |
| Percentage |
| Gender | ||||||||
| Male | 1222 | 76.5% | 465 | 77% | 1979 | 82% | 754 | 81% |
| Female | 375 | 23.5% | 137 | 23% | 445 | 18% | 181 | 19% |
| Race/ethnicity* | ||||||||
| Black | 771 | 48.3% | 194 | 32% | 789 | 33% | 280 | 30% |
| White | 634 | 39.7% | 332 | 55% | 1356 | 56% | 556 | 59% |
| Hispanic (any race) | 151 | 9.5% | 177 | 30% | 655 | 27% | 253 | 27% |
| Other | 41 | 2.6% | 75 | 12% | 272 | 11% | 99 | 11% |
| Educational attainment | ||||||||
| Less than high school diploma/equivalency | 293 | 18.5% | 168 | 28% | 680 | 32% | 135 | 29% |
| High school diploma/equivalency | 399 | 25.2% | 114 | 19% | 486 | 23% | 126 | 27% |
| Some college/associate's degree | 622 | 39.2% | 183 | 31% | 596 | 28% | 134 | 28% |
| Bachelor degree | 169 | 10.6% | 80 | 13% | 240 | 11% | 38 | 8% |
| Graduate degree/graduate work | 102 | 6.4% | 54 | 9% | 155 | 7% | 40 | 8% |
| Current ARV medication use | 1122 | 70.8% | 556 | 92% | 1940 | 80% | 490 | 52% |
| HIV risk category | ||||||||
| IV drug use | 167 | 14.1% | 122 | 20% | 598 | 25% | 271 | 29% |
| Homosexual sexual contact | 608 | 51.2% | 285 | 47% | 1109 | 46% | 366 | 39% |
| Heterosexual sexual contact | 358 | 30.2% | 162 | 27% | 538 | 22% | 173 | 19% |
| Other | 54 | 4.5% | 33 | 5% | 182 | 7% | 125 | 13% |
| Demographics and HIV characteristics (cont.) | Value | Value | Value | Value | ||||
| Age | ||||||||
| 25th percentile | 38 | 42 | 38 | 41 | ||||
| Median | 43 | 51 | 44 | 48 | ||||
| 75th percentile | 49 | 61 | 52 | 56 | ||||
| CD4 count | ||||||||
| 25th percentile | 264 | 157 | 46 | 16 | ||||
| Median | 421 | 364 | 156.5 | 84 | ||||
| 75th percentile | 463 | 594 | 371 | 247 | ||||
| Log plasma viral load | ||||||||
| 25th percentile | Undetectable | 1.60 | 1.70 | 1.70 | ||||
| Median | 2.28 | 1.70 | 2.70 | 3.65 | ||||
| 75th percentile | 4.06 | 2.79 | 4.53 | 5.12 | ||||
The CHARTER cross-sectional study includes all CHARTER participants (those who did and did not recruit into a longitudinal substudy). The NNTC active cohort is currently enrolled and being followed on study. The longitudinal NNTC cohort includes both members of the active cohort and inactive participants. The NNTC tissue bank cohort includes all study participants who are deceased with autopsy. *The race/ethnicity data for the CHARTER study are collected in a single, mutually exclusive question; the data for NNTC are collected using separate race and ethnicity questions and are not mutually exclusive.
Figure 1Number of data collection visits conducted (red line) and number and types of biospecimens collected of type (colored bars) for each year of the CHARTER and NNTC clinical research studies. Data and biospecimen collection for the NNTC clinical research study is ongoing, data are through September, 2018.
Figure 2Participant intersections in the external, experimental database measurement classes. Orange bars show the number of unique individuals represented in that measurement class in the external database. Vertical, blue bars show the number of unique participants co-represented across the measurement classes (connected dots) in the experimental database.
Figure 3A) The effect of standardized missing data and ARV codes on downstream ‘current ARV regimen’ variable. ARV codes were standardized to the NIH ARV drug name abbreviations (e.g. for the participants with IDs 04204 and 04264 TFV was used as an abbreviation for tenofovir disoproxil fumarate, which was then standardized to TDF). Nonstandard missing start dates for ARVs resulted in an underestimation of drugs in the regimen. Correction of the missing data to the correct code (99/99/9999) shows that three ARVs were included in the drug regimen of participant with ID 04264, where previously none were included. B) Educational attainment was collected using an open-ended question item. The raw data contained personal information (concealed here) and were not readily useful for analytical models. Natural language processing was used to operationalize an ordered categorical educational attainment variable (right) from the raw data (left).